DZD6008 + pemetrexed + carboplatin

This drug refers to a **combination therapy** involving DZD6008, pemetrexed, and carboplatin, investigated primarily for use in patients with advanced non-small cell lung cancer (NSCLC) that harbor EGFR mutations. DZD6008 is an investigational compound undergoing Phase 1 clinical evaluation; its mechanism relates to targeting the epidermal growth factor receptor (EGFR), which plays a central role in cell proliferation signaling pathways in cancer. Pemetrexed is a multi-targeted antifolate cytotoxic agent that inhibits the synthesis of DNA and RNA by blocking folate-dependent enzymes, and carboplatin is a platinum-based chemotherapy that induces DNA crosslinking and apoptosis. The regimen is delivered intravenously, aiming to provide synergistic antitumor effects and maximize efficacy in EGFR-mutant NSCLC[3][2][4][6].

Other names

pemetrexedcarboplatin